You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

CLINICAL TRIALS PROFILE FOR ZANAMIVIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zanamivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00540501 ↗ A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects Withdrawn GlaxoSmithKline Phase 1 2007-10-01 This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed GlaxoSmithKline Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed Mount Sinai Hospital, Canada Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zanamivir

Condition Name

Condition Name for Zanamivir
Intervention Trials
Influenza, Human 11
Influenza 10
Bioequivalence 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zanamivir
Intervention Trials
Influenza, Human 23
Infections 5
Infection 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zanamivir

Trials by Country

Trials by Country for Zanamivir
Location Trials
United States 113
Canada 14
Australia 14
China 11
Thailand 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zanamivir
Location Trials
Texas 6
New York 5
Missouri 5
Kentucky 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zanamivir

Clinical Trial Phase

Clinical Trial Phase for Zanamivir
Clinical Trial Phase Trials
Phase 4 3
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zanamivir
Clinical Trial Phase Trials
Completed 22
Terminated 3
Withdrawn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zanamivir

Sponsor Name

Sponsor Name for Zanamivir
Sponsor Trials
GlaxoSmithKline 13
Novagenix Bioanalytical Drug R&D Center 5
University of Oxford 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zanamivir
Sponsor Trials
Other 37
Industry 21
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.